ArticleResearch and practice in thrombosis and haemostasis2020
Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting.
Article in Research and practice in thrombosis and haemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Tissue factor detection in mouse tissues by western blotting using commercial antibodies.Research and practice in thrombosis and haemostasis · 2026Article
- Long-term Storage of Diluted Antibody in Tris-buffered Saline with Tween 20.Biological procedures online · 2025Article
- Optimization of a Western blot protocol for the detection of low levels of tissue factor in human cells.Research and practice in thrombosis and haemostasis · 2025Article
- Challenges with measuring tissue factor antigen and activity in human plasma.Blood vessels, thrombosis & hemostasis · 2024Review
- Brain organoids engineered to give rise to glia and neural networks after 90 days in culture exhibit human-specific proteoforms.Frontiers in cellular neuroscience · 2024Article
- Commentary: Macrophage IL-1β-positive microvesicles exhibit thrombo-inflammatory properties and are detectable in patients with active juvenile idiopathic arthritis.Frontiers in immunology · 2024Article
- Evaluation of the ability of commercial enzyme-linked immunosorbent assays to measure mouse tissue factor.Research and practice in thrombosis and haemostasis · 2024Article
- Monocyte Tissue Factor Expression: Lipopolysaccharide Induction and Roles in Pathological Activation of Coagulation.Thrombosis and haemostasis · 2023Review
- Western blot and immunohistochemical analysis of mouse tissue factor.Research and practice in thrombosis and haemostasis · 2023Article
- Article
- Evaluation of four commercial ELISAs to measure tissue factor in human plasma.Research and practice in thrombosis and haemostasis · 2023Article
- Platelet activation by SARS-CoV-2 implicates the release of active tissue factor by infected cells.Blood advances · 2022Article
- Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer: Comment by Mackman et al.Cancer science · 2022Article
- Suitability of GRK Antibodies for Individual Detection and Quantification of GRK Isoforms in Western Blots.International journal of molecular sciences · 2022Article
- Platelet extracellular vesicles in COVID-19: Potential markers and makers.Journal of leukocyte biology · 2022Review
- Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.Blood advances · 2021Article
- BRCA1 Antibodies Matter.International journal of biological sciences · 2021Article
- Evaluation of different commercial antibodies for their ability to detect human and mouse tissue factor by western blotting.Research and practice in thrombosis and haemostasis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundWestern blotting is used to measure protein expression in cells and tissues. Appropriate interpretation of resulting data is contingent upon antibody validation.
objectivesWe assessed several commercial anti-human and anti-mouse tissue factor (TF) antibodies for their ability to detect TF by western blotting. MATERIAL AND
methodsWe used human pancreatic cancer cell lines expressing different levels of TF and a mouse pancreatic cancer cell line expressing TF with a matched knockout derivative.
resultsHuman and mouse TF protein detected by western blotting correlated with levels of TF mRNA in these cell lines. The apparent molecular weight of TF is increased by N-linked glycosylation and, as expected, deglycosylation decreased the size of TF based on western blotting. We found that four commercial anti-human TF antibodies detected TF in a TF-positive cell line HPAF-II whereas no signal was observed in a TF-negative cell line MIA PaCa-2. More variability was observed in detecting mouse TF. Two anti-mouse TF antibodies detected mouse TF in a TF-positive cell line and no signal was observed in a TF knockout cell line. However, a third anti-mouse TF antibody detected a nonspecific protein in both the mouse TF-positive and TF-negative cell lines. Two anti-human TF antibodies that are claimed to cross react with mouse TF either recognized a nonspecific band or did not detect mouse TF. DISCUSSION: Our results indicate that there is a range in quality of commercial anti-TF antibodies.
conclusionWe recommend that all commercial antibodies should be validated to ensure that they detect TF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.